New drug duo aims to slow advanced lung cancer in first-line treatment
NCT ID NCT07183189
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 27 times
Summary
This phase 3 study tests whether adding SHR-A2009 to aumolertinib works better than aumolertinib alone for people with advanced EGFR-mutant non-small cell lung cancer who haven't had treatment yet. About 576 adults aged 18-75 will join. The main goal is to see if the combo delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact
Conditions
Explore the condition pages connected to this study.